Invesco
EIGR

Invesco’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Invesco’s Portfolio EIGR Stock Details EIGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-584
Closed -$15.7K – 3984
2023
Q1 		$15.7K Buy
584
+102
+21% +$4.74K ﹤0.01% 3823
2022
Q4 		$17K Sell
482
-54
-10% -$6.49K ﹤0.01% 3984
2022
Q3 		$121K Buy
536
+67
+14% +$16.5K ﹤0.01% 3801
2022
Q2 		$89K Buy
+469
New +$94.5K ﹤0.01% 3906
2021
Q4 		– Sell
-382
Closed -$76K – 4119
2021
Q3 		$76K Buy
382
+45
+13% +$10.7K ﹤0.01% 3973
2021
Q2 		$86K Buy
+337
New +$84.1K ﹤0.01% 3912

Other funds holding EIGR

Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
RC
RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Invesco's EIGR Position: Q2 2023 in Review

Invesco sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q2 2023, closing a stake of 584 shares — an estimated $15.7K sold.

Invesco first reported a position in EIGR in Q2 2021 and held it in 6 quarters. The position peaked at $121K in Q3 2022. 66 funds tracked by Wall St. Rank hold EIGR as of Q2 2023.

  • Invesco reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q2 2023 after selling out during the quarter.
  • Invesco sold 584 Eiger BioPharmaceuticals, Inc. shares in Q2 2023, an estimated $15.7K.
  • Invesco first reported a position in Eiger BioPharmaceuticals, Inc. in Q2 2021 and held it in 6 quarters.
  • Invesco's Eiger BioPharmaceuticals, Inc. position peaked at $121K in Q3 2022.
  • 66 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q2 2023.

Based on Invesco's 13F filing for Q2 2023, filed 11 Aug 2023.